These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 24836206)
1. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now? O'Sullivan BP Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206 [No Abstract] [Full Text] [Related]
2. Ignoring the nonsense: a phase II trial in cystic fibrosis. Hyde SC; Gill DR Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009 [No Abstract] [Full Text] [Related]
3. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008 [TBL] [Abstract][Full Text] [Related]
4. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids. Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232 [TBL] [Abstract][Full Text] [Related]
5. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives. Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488 [TBL] [Abstract][Full Text] [Related]
7. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment of the basic defect in cystic fibrosis. Roomans GM Cell Biol Int; 2014 Nov; 38(11):1244-6. PubMed ID: 24809326 [TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
10. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Aslam A; Jahnke N; Remmington T; Southern KW Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196 [No Abstract] [Full Text] [Related]
11. Ataluren in cystic fibrosis: development, clinical studies and where are we now? Zainal Abidin N; Haq IJ; Gardner AI; Brodlie M Expert Opin Pharmacother; 2017 Sep; 18(13):1363-1371. PubMed ID: 28730885 [TBL] [Abstract][Full Text] [Related]
12. Drug developers aim to treat cystic fibrosis through disease modification. Thompson CA Am J Health Syst Pharm; 2008 Dec; 65(24):2310-2. PubMed ID: 19052266 [No Abstract] [Full Text] [Related]